These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 16453263)

  • 1. Live attenuated influenza vaccine is safe and immunogenic in immunocompromised ferrets.
    Huber VC; McCullers JA
    J Infect Dis; 2006 Mar; 193(5):677-84. PubMed ID: 16453263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
    Fleming DM; Crovari P; Wahn U; Klemola T; Schlesinger Y; Langussis A; Øymar K; Garcia ML; Krygier A; Costa H; Heininger U; Pregaldien JL; Cheng SM; Skinner J; Razmpour A; Saville M; Gruber WC; Forrest B;
    Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials.
    Rhorer J; Ambrose CS; Dickinson S; Hamilton H; Oleka NA; Malinoski FJ; Wittes J
    Vaccine; 2009 Feb; 27(7):1101-10. PubMed ID: 19095024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults.
    King JC; Treanor J; Fast PE; Wolff M; Yan L; Iacuzio D; Readmond B; O'Brien D; Mallon K; Highsmith WE; Lambert JS; Belshe RB
    J Infect Dis; 2000 Feb; 181(2):725-8. PubMed ID: 10669363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a candidate live attenuated influenza vaccine prepared in Changchun BCHT (China) for safety and efficacy in ferrets.
    Shen Z; Bowen RA; Ge P; Yu J; Shen Y; Kong W; Jiang C; Wu J; Zhu C; Xu Y; Wei W; Rudenko L; Kiseleva I; Xu F
    Vaccine; 2016 Nov; 34(48):5953-5958. PubMed ID: 27997342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
    Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE
    Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.
    Mallory RM; Yi T; Ambrose CS
    Vaccine; 2011 Jun; 29(26):4322-7. PubMed ID: 21513761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer.
    Carr S; Allison KJ; Van De Velde LA; Zhang K; English EY; Iverson A; Daw NC; Howard SC; Navid F; Rodriguez-Galindo C; Yang J; Adderson EE; McCullers JA; Flynn PM
    J Infect Dis; 2011 Nov; 204(10):1475-82. PubMed ID: 21949042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine-specific antibody secreting cells are a robust early marker of LAIV-induced B-cell response in ferrets.
    Cherukuri A; Servat E; Woo J
    Vaccine; 2012 Jan; 30(2):237-46. PubMed ID: 22080173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children.
    Bracco Neto H; Farhat CK; Tregnaghi MW; Madhi SA; Razmpour A; Palladino G; Small MG; Gruber WC; Forrest BD;
    Pediatr Infect Dis J; 2009 May; 28(5):365-71. PubMed ID: 19395948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity.
    Belshe RB; Coelingh K; Ambrose CS; Woo JC; Wu X
    Vaccine; 2010 Feb; 28(9):2149-56. PubMed ID: 20003926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults.
    Block SL; Yi T; Sheldon E; Dubovsky F; Falloon J
    Vaccine; 2011 Nov; 29(50):9391-7. PubMed ID: 21983154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
    Ashkenazi S; Vertruyen A; Arístegui J; Esposito S; McKeith DD; Klemola T; Biolek J; Kühr J; Bujnowski T; Desgrandchamps D; Cheng SM; Skinner J; Gruber WC; Forrest BD;
    Pediatr Infect Dis J; 2006 Oct; 25(10):870-9. PubMed ID: 17006279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
    King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
    Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model.
    Rudenko L; Kiseleva I; Krutikova E; Stepanova E; Rekstin A; Donina S; Pisareva M; Grigorieva E; Kryshen K; Muzhikyan A; Makarova M; Sparrow EG; Torelli G; Kieny MP
    PLoS One; 2018; 13(12):e0208028. PubMed ID: 30507951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007.
    Skowronski DM; De Serres G; Dickinson J; Petric M; Mak A; Fonseca K; Kwindt TL; Chan T; Bastien N; Charest H; Li Y
    J Infect Dis; 2009 Jan; 199(2):168-79. PubMed ID: 19086914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma.
    Safdar A; Rodriguez MA; Fayad LE; Rodriguez GH; Pro B; Wang M; Romaguera JE; Goy AH; Hagemeister FB; McLaughlin P; Bodey GP; Kwak LW; Raad II; Couch RB
    J Infect Dis; 2006 Nov; 194(10):1394-7. PubMed ID: 17054068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of seasonal live attenuated influenza vaccine against virus replication and transmission of a pandemic 2009 H1N1 virus in ferrets.
    Pearce MB; Belser JA; Houser KV; Katz JM; Tumpey TM
    Vaccine; 2011 Apr; 29(16):2887-94. PubMed ID: 21338676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.